The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin

Molecular Pharmaceutics

Volumn 9, Issue 6, 2012, Pages 1822-1833

  Shen, Ding Wu ^a   Pouliot, Lynn M ^a,c   Gillet, Jean Pierre ^a   Ma, Wenting ^a   Johnson, Alfred C ^b   Hall, Matthew D ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapy; cisplatin; cisplatin resistance; cytoskeleton; doxorubicin; trafficking

Indexed keywords

ACTIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; REPRESSOR PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GCF2; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL SURFACE; CYTOPLASM; CYTOSKELETON; DOWNSTREAM PROCESSING; DRUG ACCUMULATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SENSITIVITY ANALYSIS;

CELL LINE, TUMOR; CISPLATIN; CYTOSKELETON; DOXORUBICIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; PROTEIN TRANSPORT; RHOA GTP-BINDING PROTEIN; RNA-BINDING PROTEINS;

EID: 84862003012     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300153z     Document Type: Article

References (45)

1. Niedner, H.; Christen, R.; Lin, X.; Kondo, A.; Howell, S. B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacol. 2001, 60, 1153-1160. (Pubitemid 33144883)
2. Francia, G.; Man, S.; Teicher, B.; Grasso, L.; Kerbel, R. S. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol. Cell. Biol. 2004, 24, 6837-6849. (Pubitemid 38944361)
3. Yasui, K.; Mihara, S.; Zhao, C.; Okamoto, H.; Saito-Ohara, F.; Tomida, A.; Funato, T.; Yokomizo, A.; Naito, S.; Imoto, I.; Tsuruo, T.; Inazawa, J. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004, 64, 1403-1410. (Pubitemid 38235609)
4. Roberts, D.; Schick, J.; Conway, S.; Biade, S.; Laub, P. B.; Stevenson, J. P.; Hamilton, T. C.; O'Dwyer, P. J.; Johnson, S. W. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br. J. Cancer 2005, 92, 1149-1158. (Pubitemid 40546683)
5. Yang, H.; Kong, W.; He, L.; Zhao, J. J.; O'Donnell, J. D.; Wang, J.; Wenham, R. M.; Coppola, D.; Kruk, P. A.; Nicosia, S. V.; Cheng, J. Q. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68, 425-433. (Pubitemid 351380068)
6. Martin, L. P.; Hamilton, T. C.; Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14, 1291-1295. (Pubitemid 351413906)
7. Hall, M. D.; Okabe, M.; Shen, D. W.; Liang, X. J.; Gottesman, M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495-535. (Pubitemid 351738162)
8. Liang, X. J.; Shen, D. W.; Garfield, S.; Gottesman, M. M. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res. 2003, 63, 5909-5916. (Pubitemid 37187492)
9. Shen, D. W.; Su, A.; Liang, X. J.; Pai-Panandiker, A.; Gottesman, M. M. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 2004, 91, 270-276. (Pubitemid 39037071)
10. Heasman, S. J.; Ridley, A. J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9, 690-701.
11. Lu, Q.; Longo, F. M.; Zhou, H.; Massa, S. M.; Chen, Y. H. Signaling through Rho GTPase pathway as viable drug target. Curr. Med. Chem. 2009, 16, 1355-1365.
12. Miller, A. L.; Bement, W. M. Regulation of cytokinesis by Rho GTPase flux. Nat. Cell Biol. 2009, 11, 71-77.
13. Navenot, J. M.; Fujii, N.; Peiper, S. C. Activation of Rho and Rho-associated kinase by GPR54 and KiSS1 metastasis suppressor gene product induces changes of cell morphology and contributes to apoptosis. Mol. Pharmacol. 2009, 75, 1300-1306.
14. Yoshida, T.; Clark, M. F.; Stern, P. H. The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival. J. Cell. Biochem. 2009, 106, 896-902.
15. Sin, W. C.; Chen, X. Q.; Leung, T.; Lim, L. RhoA-binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network. Mol. Cell. Biol. 1998, 18, 6325-6339. (Pubitemid 28500523)
16. Jin, L. M. Rock 'n' Rho: regulation of ion channels. Am. J. Physiol. 2009, 296, H908-H909.
17. Wu, D.; Asiedu, M.; Wei, Q. Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDAMB- 231 breast cancer cells through activation of RhoA and RhoC. Oncogene 2009, 28, 2219-2230.
18. Ohtsuka, H.; Oikawa, M.; Ariake, K.; Rikiyama, T.; Motoi, F.; Katayose, Y.; Unno, M.; Johnson, A. C. GC-binding factor 2 interacts with dishevelled and regulates Wnt signaling pathways in human carcinoma cell lines. Int. J. Cancer 2011, 129, 1599-1610.
19. Kageyama, R.; Pastan, I. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 1989, 59, 815-825.
20. Khachigian, L. M.; Santiago, F. S.; Rafty, L. A.; Chan, O. L.; Delbridge, G. J.; Bobik, A.; Collins, T.; Johnson, A. C. GC factor 2 represses platelet-derived growth factor A-chain gene transcription and is itself induced by arterial injury. Circ. Res. 1999, 84, 1258-1267. (Pubitemid 29270040)
21. Rikiyama, T.; Curtis, J.; Oikawa, M.; Zimonjic, D. B.; Popescu, N.; Murphy, B. A.; Wilson, M. A.; Johnson, A. C. GCF2: expression and molecular analysis of repression. Biochim. Biophys. Acta 2003, 1629, 15-25. (Pubitemid 37186774)
22. Suriano, A. R.; Sanford, A. N.; Kim, N.; Oh, M.; Kennedy, S.; Henderson, M. J.; Dietzmann, K.; Sullivan, K. E. GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Mol. Cell. Biol. 2005, 25, 9073-9081. (Pubitemid 41429095)
23. Reed, A. L.; Yamazaki, H.; Kaufman, J. D.; Rubinstein, Y.; Murphy, B.; Johnson, A. C. Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor. J. Biol. Chem. 1998, 273, 21594-21602. (Pubitemid 28405329)
24. Shen, D.; Pastan, I.; Gottesman, M. M. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res. 1998, 58, 268-275. (Pubitemid 28047066)
25. Shen, D. W.; Liang, X. J.; Gawinowicz, M. A.; Gottesman, M. M. Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol. Pharmacol. 2004, 66, 789-793. (Pubitemid 39319450)
26. Orina, J. N.; Calcagno, A. M.; Wu, C. P.; Varma, S.; Shih, J.; Lin, M.; Eichler, G.; Weinstein, J. N.; Pommier, Y.; Ambudkar, S. V.; Gottesman, M. M.; Gillet, J. P. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol. Cancer Ther. 2009, 8, 2057-2066.
27. May, J. A.; Ratan, H.; Glenn, J. R.; Losche, W.; Spangenberg, P.; Heptinstall, S. GPIIb-IIIa antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin D. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly. Platelets 1998, 9, 227-232. (Pubitemid 28312684)
28. Liang, X. J.; Yin, J. J.; Taylor, B.; Winkovitch, S. M.; Garfield, S. H.; Shen, D. W.; Gottesman, M. M.; Aszalos, A. Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines. Cancer Chemother. Pharmacol. 2008, 62, 977-984.
29. Calcagno, A. M.; Salcido, C. D.; Gillet, J. P.; Wu, C. P.; Fostel, J. M.; Mumau, M. D.; Gottesman, M. M.; Varticovski, L.; Ambudkar, S. V. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 2010, 102, 1637-1652.
30. Gillet, J. P.; Gottesman, M. M. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol. 2010, 596, 47-76.
31. Matas, O. B.; Fritz, S.; Luna, A.; Egea, G. Membrane trafficking at the ER/Golgi interface: functional implications of RhoA and Rac1. Eur. J. Cell Biol. 2005, 84, 699-707. (Pubitemid 41149293)
32. Millman, E. E.; Zhang, H.; Zhang, H.; Godines, V.; Bean, A. J.; Knoll, B. J.; Moore, R. H. Rapid recycling of beta-adrenergic receptors is dependent on the actin cytoskeleton and myosin Vb. Traffic 2008, 9, 1958-1971.
33. Ridley, A. J. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006, 16, 522-529. (Pubitemid 44444995)
34. Jaffe, A. B.; Hall, A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 2005, 21, 247-269. (Pubitemid 41740635)
35. Ridley, A. J. Rho proteins: linking signaling with membrane trafficking. Traffic 2001, 2, 303-310. (Pubitemid 32487560)
36. Shen, D. W.; Pouliot, L. M.; Hall, M. D.; Gottesman, M. M. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacol. Rev. 2012, in press.
37. Stossel, T. P.; Condeelis, J.; Cooley, L.; Hartwig, J. H.; Noegel, A.; Schleicher, M.; Shapiro, S. S. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell Biol. 2001, 2, 138-145. (Pubitemid 33674042)
38. Thelin, W. R.; Chen, Y.; Gentzsch, M.; Kreda, S. M.; Sallee, J. L.; Scarlett, C. O.; Borchers, C. H.; Jacobson, K.; Stutts, M. J.; Milgram, S. L. Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J. Clin. Invest. 2007, 117, 364-374. (Pubitemid 46203965)
39. Hader, C.; Marlier, A.; Cantley, L. Mesenchymal-epithelial transition in epithelial response to injury: the role of Foxc2. Oncogene 2009, 29, 1031-1040.
40. Hasegawa, H.; Kakuguchi, W.; Kuroshima, T.; Kitamura, T.; Tanaka, S.; Kitagawa, Y.; Totsuka, Y.; Shindoh, M.; Higashino, F. HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells. Br. J. Cancer 2009, 100, 1943-8.
41. Kurooka, H.; Yokota, Y. Nucleo-cytoplasmic shuttling of Id2, a negative regulator of basic helix-loop-helix transcription factors. J. Biol. Chem. 2005, 280, 4313-4320. (Pubitemid 40288599)
42. Verhagen, J.; Donnelly, M.; Elliott, G. Characterization of a novel transferable CRM-1-independent nuclear export signal in a herpesvirus tegument protein that shuttles between the nucleus and cytoplasm. J. Virol. 2006, 80, 10021-10035. (Pubitemid 44522596)
43. Tedesco, M.; La Sala, G.; Barbagallo, F.; De Felici, M. Farini, D. STRA8 shuttles between nucleus and cytoplasm and displays transcriptional activity. J. Biol. Chem. 2009, 284, 35781-35793.
44. Barone, S.; Fussell, S. L.; Singh, A. K.; Lucas, F.; Xu, J.; Kim, C.; Wu, X.; Yu, Y.; Amlal, H.; Seidler, U.; Zuo, J.; Soleimani, M. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J. Biol. Chem. 2009, 284, 5056-5066.
45. Laird, D. W. Closing the gap on autosomal dominant connexin- 26 and connexin-43 mutants linked to human disease. J. Biol. Chem. 2008, 283, 2997-3001.